Proteon PharmaceuticalsS.A.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2011-02-01
Share capital
1 243 961,60 PLN
Registered address
Tylna 3A, 90-364 Łódź, Poland
Website
Email
Email address current
Electronic delivery address
AE:PL-93353-53390-CEGRH-24

Financials

The financial statement for 2025 has not yet been filed with the Financial Document Repository (past deadline).

Revenue history (in k)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2024.

Results vs industry

Revenue
This companyUSD 2.03mMedianUSD 38.31kAverageUSD 2.31m
Net profit
This companyUSD -8.72mMedianUSD -1.50kAverageUSD -84.98k
Operating costs
This companyUSD 7.77mMedianUSD 56.25kAverageUSD 2.29m
Assets
This companyUSD 12.66mMedianUSD 116.77kAverageUSD 2.72m

Bank accounts

Registered as a VAT taxpayer on 2005-06-02. Active

Debt

5 active proceedings recorded in KRZ. Active proceeding

Registration dateProceeding typeStatus
Feb 3, 2026
Petition to declare entrepreneur bankruptcy
Joined
Dec 15, 2025
Petition to declare entrepreneur bankruptcy
In progress
Jan 26, 2026
Complaint against a decision in accelerated arrangement proceedings
Closed
Jul 29, 2025
Accelerated arrangement proceedings
Closed
Jul 2, 2025
Petition to open accelerated arrangement proceedings
Closed

MSiG notices

47 notices recorded in the Court and Commercial Gazette (MSiG).

Publication dateEvent
Feb 17, 2026Shareholders' meeting convened
Jan 29, 2026Shareholders' meeting convened
Nov 27, 2025Shareholders' meeting convened
Nov 13, 2025Shareholders' meeting convened
Oct 22, 2025Shareholders' meeting convened

Public aid

15 public aid cases recorded, with a total value of $12,464,408.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
—
Regional investment aid
—
Aid for SME access to finance — risk finance aid
—

Tenders

No recorded participation in tenders.

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Authorized Representatives

Manner of representation

In the case of a one-person management board, one member of the management board acting independently is authorized to make declarations of will on behalf of the company. In the case of a management board consisting of two or more members, two members of the management board acting jointly are authorized to make declarations of will on behalf of the company.

Supervisory board

Sergejs Iljasenko — Supervisory Board Member
Paweł Kowalczyk — Supervisory Board Member

Beneficial owners

Person
Bruno Maineult (57)

Subsidiaries

NameStake
100%

Competitors

Name
MedappS.A.
BiotechnaS.A.
Read-GeneS.A.
SkinlabP.S.A.
EIT Rawmaterials Clc Eastsp. z o.o.
FamicordtxS.A.
Centrum Innowacji i Wdrożeń Bio-Inwestsp. z o.o.
COS LabP.S.A.
Syventosp. z o.o.
UveraS.A.

Change history

DateEvent
2025-04-07Share capital change
2024-08-21Share capital change
2024-07-22Share capital change
2024-07-11Share capital change
2023-03-17Share capital change

FAQ

Last updated: 2026-09-25